Epilepsy. Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
Conditions
Interventions
Intervention 1: Intervention group: It will be the first trial targeting medication adherence through an online mindfulness intervention.Each week, the intervention group will receive an email from th
Sponsors
National Institute for Medical Research Development
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: A confirmed diagnosis of epilepsy in patients by a physician specializing in neurology An age of 18 years or older Prescribing antiepileptic drugs Being responsible for taking the medicine by oneself or an independent person
Exclusion criteria
Exclusion criteria: Suffering from progressive neurological disease Do not prescribed antiepileptic drugs Diagnosis of an intellectual disability Having a major cognitive impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The medication adherence score. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: The Medication Adherence Report Scale(MARS).;Mindful Attention Awareness score. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Mindful Attention Awareness Scale(MAAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of a patient's seizures score. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Liverpool Seizure Severity Scale(LSSS).;Quality of life in epilepsy score. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Health-related quality of life.;Perceived behavioral control questions. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Perceived behavioral control(PBC).;Anxiety and depression score. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Hospital Anxiety and Depression Scale (HADS).;Patient's beliefs about medication. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Beliefs about Medications Questionnaire (BMQ).;Intention to adhere to medication. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Behavioral intention Questions.;Self-monitoring by the patient in taking his medications. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Self-monitoring questions.;Plan for time, place, how to take medicine. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Questions about Action planning.;Predicting drug use barriers and creating strategies to overcome those barriers. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Questions about Coping planning.;Investigation of automatic drug use by patients with epilepsy. Timepoint: Immediately after the intervention and 6 months after the intervention. Method of measurement: Self-Report Behavioural Automaticity Index (SRBAI). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Pakpour
Qazvin University of Medical Sciences
Outcome results
None listed